“SEA” THE POTENTIAL: MARINE BIODIVERSITY FOR INNOVATIVE DISCOVERIES
Unlocking the power of marine biodiversity to discover cutting-edge bioactive compounds
EUREMAP is developing a multi-purpose service platform to discover new bioactive compounds that are not limited to any particular natural product or application. A broad range of companies from different sectors, from pharmaceutical and nutraceutical to agriculture and aquaculture, will benefit from the marine bioprospecting service platform that EUREMAP will offer.
During the project, we proactively contact industrial end-users and organise roundtables and thematic working groups on several themes, such as common access procedures, industry needs and priorities, pipelines for industrial end-users and common rules for the use and valorisation of pipeline assets (check out our Pillar 6).
UNIQUE PLATFORM
What makes EUREMAP unique?
Access to much more than infrastructure – tap into a powerhouse of marine innovation.
Not just equipment
meet the expertsEUREMAP is a consortium of leading European research infrastructures. Behind every tool and technology is a team of top scientists ready to co-create with you.
One access point
many partnersScience with purpose
sustainability firstPersonalized guidance for everyone
Whether you’re new to bioprospecting or experienced, we tailor support to your needs — from first steps to full-scale projects. We help turn ideas (or waste) into value.
DEFINING INDUSTRY
EUREMAP welcomes collaboration with a broad range of industrial and research players:
- Large pharmaceutical, cosmetics, nutraceutical, agriculture, aquaculture and biotech companies with active R&D pipelines
- SMEs and start-ups exploring marine-derived innovation
- Companies with bio-waste looking for valorisation opportunities
- Academic spin-offs and cross-sector initiatives
- Other research infrastructures seeking partnerships
- Academic researchers with early-stage results and an interest in exploring valorisation potential
Whether you have a defined need or just a curiosity – we can support and guide you.
LEGAL SUPPORT – WE’VE GOT YOU COVERED
We understand that legal uncertainties in natural products bioprospecting can limit innovation.
At EUREMAP, we:
- Operate under confidentiality and a NDA can be signed after first meeting
- Use Material Transfer Agreements (MTAs) and standardized contracting models to ensure clarity
- Check out our General Terms for Service Contracts
- Provide guidance on Nagoya Protocol and Access and Benefit-Sharing (ABS) compliance
Share clear info about the origin and legal status of all biological material - Help you understand your legal obligations – no surprises
You focus on innovation. We’ll take care of the framework.
TRY OUR BIOPROSPECTING PIPELINE – LET YOUR IDEA GROW
Call for collaboration – Turn your challenge into a demonstrator project:
Are you active in pharma, cosmetics, biotech, food, agriculture, or exploring new ways to valorise your waste streams? Discover the untapped potential of marine bioprospecting with EUREMAP.
We are inviting companies to test our integrated service pipeline through short, collaborative demonstrator projects. This is a unique opportunity to explore what marine resources can mean for your business – from genomics and biomass to synthesis. Check our service pipeline.
More information about the call here
Register your interest via a short form – it only takes a few minutes
👉 Registration form here
📅 Call open from 17 June to 31 August 2025
An NDA can be signed during or after of this meeting!
GET IN TOUCH
During the project, we proactively contact industrial end-users and organise roundtables and thematic working groups on several themes, such as common access procedures, industry needs and priorities, pipelines for industrial end-users and common rules for the use and valorisation of pipeline assets (check out our Pillar 6).
Want to know more or explore possibilities? We’re happy to talk – Contact Us
INDUSTRY ADVISORY BOARD
Gema Santamaría Núñez
Gema Santamaría Núñez is a senior molecular biologist and Team Leader at PharmaMar’s Cellular Biology R&D department. With over 20 years of experience in translational research, she holds dual BSc degrees in Biochemistry and Biological Sciences, and a PhD in Molecular Biology from Universidad Autónoma de Madrid. Her research has led to key mechanistic insights into lurbinectedin, contributing to its FDA approval in 2020. Gema’s work focuses on drug screening, molecular mechanisms of antitumor compounds, and therapeutic innovation. She holds patents in drug combinations and previously worked at Genómica S.A.U., deepening her expertise in molecular diagnostics and cancer biology.
Carlos Unamunzaga
Co-founder of Fitoplancton Marino, S.L. in 2002. and CEO (2004-2023). Actual President of the EABA (European Algae Biomass Association).
Master’s Degree in Marine Sciences at the University of Cadiz, Spain (2000) and a Master Degree in Internationalization of SME’s by the EOI Business School (2004).
Expert in Nutrition, Novel Foods and Regulatory affairs for microalgae. Management of preclinical and clinical trials for algae ingredients, health claims substantiation, Intelectual Property management and overall Health Science related activities. Holds 3 International patents.
Franck Hennequart
Franck Hennequart is an engineer specialized in marine biotechnology, with academic training from the University of Caen. He began his career in aquaculture research and technology transfer in Canada before moving to Ireland, where he worked at NUI Galway and co-founded OGT, a seaweed extract company. After OGT’s acquisition by Tradecorp (now Rovensa Next), he became Global Seaweed Project Manager. In 2016, Franck co-founded ALGAIA, a French company producing bioactive seaweed-based ingredients. As Managing Director of ALGAIA’s research center in Normandy, he also advises on algae valorization. He is a shareholder in SEANEO, a consultancy for aquaculture and marine ecosystems.
